$ELYM News
Last published 2y ago
- 2y agoELYMEliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.GlobeNewswireName change to "Climb Bio" marks the Company's transition and focus on developing treatments for immune-mediated diseases Climb Bio will begin trading on Nasdaq under the trading symbol "CLYM"
- 2y agoELYMEliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation SummitGlobeNewswireSEATTLE and CAMBRIDGE, United Kingdom, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), announced today members of the management team will participate at the Stifel 2024 Virtual Immunology
- 2y agoELYMEliem Therapeutics Announces Additions to its Leadership TeamGlobeNewswireBrett Kaplan, M.D. appointed Chief Operating Officer Nishi Rampal, M.D. appointed Senior Vice President, Clinical Development SEATTLE and CAMBRIDGE, United Kingdom, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Eliem
- 2y agoELYMEliem Therapeutics Reports Second Quarter Financial ResultsGlobeNewswireEliem completed the acquisition of Tenet Medicines and concurrent $120 million private placement Eliem to host an Investor Day later in the year to provide an overview of budoprutug (previously referred to as TNT119),
- 2y agoELYMEliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® IndexesGlobeNewswireSEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), announced today that the Company will be included in the Russell 2000® Index and the broad-market
- 2y agoELYMEliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private PlacementGlobeNewswireEliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy Post-close
- 2y agoALPNJBTELYMHRTKuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoELYMEliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private PlacementGlobeNewswireTransaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have approximately $210 million of cash and cash equivalents, including $120
- 3y agoELYMEliem Therapeutics Announces Plans to Explore Strategic AlternativesGlobeNewswireSEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM) today announced that it has completed a review of its business, including the status of its programs,
- 3y agoELYMEliem Therapeutics Reports First Quarter Financial Results and Business HighlightsGlobeNewswirePresented initial preclinical data from ETX-123, Eliem's lead Kv7 program candidate, demonstrating a promising profile and confirming the proposed mechanism of action on neuronal excitability Additional preclinical
- 3y agoELYMEliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business HighlightsGlobeNewswireProgressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel opener program Implemented corporate reorganization and pipeline reprioritization extending cash runway into 2027
- 3y agoELYMEliem Therapeutics Provides Strategic Update and Announces Leadership TransitionGlobeNewswireCompany to focus on Kv7.2/3 channel opener program and development of lead candidate, ETX-123 Pausing clinical development of ETX-155 for Major Depressive Disorder (MDD) due to challenging capital environment
- 3y agoELYMEliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual ConferenceGlobeNewswireSEATTLE and CAMBRIDGE, United Kingdom, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability
- 3y agoELYMEliem Therapeutics Reports Third Quarter Financial and Business HighlightsGlobeNewswirePositioned to initiate ETX-155 Phase 2a trial in major depressive disorder in the first quarter of 2023 with 60-milligram dose Progressing IND-enabling studies for two Kv7 pre-candidates with safety studies planned in
- 4y agoELYMEliem Therapeutics to Participate at Two Upcoming Investor ConferencesGlobeNewswireSEATTLE and CAMBRIDGE, United Kingdom, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to
- 4y agoELYMEliem Therapeutics Provides Update on Pipeline ProgressGlobeNewswireCompany is positioned to initiate Phase 2a trial in major depressive disorder (MDD) in the first quarter of 2023 ETX-155 demonstrating exposures in single dose 60-milligram cohorts of ongoing Phase 1 pharmacokinetic trial that are consistent with prio
- 4y agoELYMEliem Therapeutics Reports Second Quarter Financial and Business HighlightsGlobeNewswireInitiated Phase 1 pharmacokinetic trial for ETX-155 with expected results in Q4 2022 Capital now expected to fund operations into 2025 SEATTLE and CAMBRIDGE, United Kingdom, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:EL
- 4y agoELYMEliem Therapeutics Provides ETX-810 Program UpdateGlobeNewswireSEATTLE and CAMBRIDGE, United Kingdom, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in
- 4y agoELYMEliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive DisorderGlobeNewswireInitiating a Phase 1 pharmacokinetics trial of ETX-155 to enable a Phase 2a trial in MDD planned to commence in first quarter of 2023 Sufficient capital expected to fund operations until mid-2024 SEATTLE and CAMBRIDGE, United Kingdom, July
- 4y agoELYMEliem Therapeutics to Host Virtual Investor Event on July 21, 2022GlobeNewswireSEATTLE and CAMBRIDGE, United Kingdom, July 07, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in
- 4y agoELYMEliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain (LSRP)GlobeNewswireTopline data from the Phase 2a clinical trial are expected in the third quarter of 2022 Virtual investor event to be held in July 2022 SEATTLE and CAMBRIDGE, United Kingdom, June 27, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-s
- 4y agoELYMEliem Therapeutics Reports First Quarter Financial and Business HighlightsGlobeNewswireSEATTLE and CAMBRIDGE, United Kingdom, May 16, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in
- 4y agoELYMEliem Provides Update on ETX-810 and ETX-155 Clinical ProgramsGlobeNewswirePhase 2a clinical trial of ETX-810 in diabetic peripheral neuropathic pain (DPNP) did not achieve the primary endpoint Phase 2a clinical trial evaluating ETX-810 in patients with lumbosacral radicular pain (LSRP) has been fully enrolled with topline d
- 4y agoELYMEliem Therapeutics Appoints Susan Franks as Senior Vice President and Head of Regulatory AffairsGlobeNewswireSEATTLE and CAMBRIDGE, United Kingdom, April 05, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in
- 4y agoELYMEliem Therapeutics to Present at Stifel's 2022 CNS DaysGlobeNewswireSEATTLE and CAMBRIDGE, United Kingdom, March 21, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in
- 4y agoELYMEliem Therapeutics Reports Fourth Quarter and Year-End Financial and Business HighlightsGlobeNewswireCompleted dosing in Phase 2a clinical trial of ETX-810 in subjects with diabetic peripheral neuropathic pain; topline data to be presented in 1H 2022 Interim data from Phase 1b clinical trial of ETX-155 in subjects with photosensitive epilepsy to be
- 4y agoELYMEliem Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswireSEATTLE and CAMBRIDGE, United Kingdom, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in
- 4y agoELYMEliem Therapeutics Host Virtual Investor Event Featuring Opinion Leaders in Chronic Pain Research on February 16, 2022GlobeNewswireSEATTLE and CAMBRIDGE, United Kingdom, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in
- 4y agoELYMEliem Therapeutics Provides Program Updates and an Overview of Expected Near-Term MilestonesGlobeNewswireETX-810 Phase 2a trial in diabetic peripheral neuropathic pain (DPNP) is fully enrolled Investigational New Drug (IND) application planned in Q1 2022 for ETX-155 Phase 2 trials in major depressive disorder (MDD) and perimenopausal depression (PMD)
- 5y agoELYMEliem Therapeutics Reports Third Quarter Financial and Business HighlightsGlobeNewswireAdvanced ETX-155 clinical development program, with the first subject successfully screened in epilepsy proof-of-concept trial and significant progress made toward the initiation of major depressive disorder (MDD) and perimenopausal depression (PMD) cli
- 5y agoELYMEliem Therapeutics to Participate at Four Upcoming Investor ConferencesGlobeNewswireSEATTLE and CAMBRIDGE, United Kingdom, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain,
- 5y agoELYMEliem Therapeutics Reports Second Quarter Financial ResultsGlobeNewswireOn track to advance two clinical programs through five proof-of-concept trials and progress two preclinical programs over the next 18-24 months Recently completed an IPO for $92 million in gross proceeds that, along with existing cash, provides cash r
- 5y agoELYMEliem Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters' Option to Purchase Additional SharesGlobeNewswireSEATTLE and CAMBRIDGE, United Kingdom, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in
- 5y agoELYMEliem Therapeutics Announces Pricing of Initial Public OfferingGlobeNewswireSEATTLE and CAMBRIDGE, United Kingdom, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain,